Summary of findings 20. Fluoxetine compared to phenelzine.
| Fluoxetine compared to phenelzine | ||||||
| Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: phenelzine | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Phenelzine | Fluoxetine | |||||
|
Failure to respond (reduction ≥ 50% on HDRS) |
150 per 1000 | 200 per 1000 (45 to 564) | OR 1.42 (0.27 to 7.34) | 40 (1 study) | ⊕⊝⊝⊝ very low1 | |
|
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0.05 standard deviations lower (0.67 lower to 0.57 higher) | 40 (1 study) | ⊕⊝⊝⊝ very low1 | This effect approaches zero | ||
| Failure to complete ‐ total ‐ | 100 per 1000 | 20 per 1000 (1 to 308) | OR 0.18 (0.01 to 4.01) | 40 (1 study) | ⊕⊝⊝⊝ very low1 | |
| Failure to complete ‐ inefficacy ‐ | 0 per 1000 (0 to 0) | Not estimable | 0 (0) | |||
| Failure to complete ‐ side effects ‐ | 50 per 1000 | 17 per 1000 (1 to 303) | OR 0.32 (0.01 to 8.26) | 40 (1 study) | ⊕⊝⊝⊝ very low1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis and less than 50 patients.